

**STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2019**

(₹ In Lakhs)

Sr No.	Particulars	Quarter ended 30.06.2019 (Unaudited)	Quarter ended 31.03.2019 (Audited)	Quarter ended 30.06.2018 (Unaudited)	Year ended 31.03.2019 (Audited)
<b>1</b>	<b>Income from Operations</b>				
	(a) Revenue from Operations	24,718	24,497	21,249	94,137
	(b) Other Operating Income	549	705	504	2,637
	<b>Total Income from Operations (Net) (a+b)</b>	<b>25,267</b>	<b>25,202</b>	<b>21,753</b>	<b>96,774</b>
<b>2</b>	<b>Other Income</b>	64	494	31	615
<b>3</b>	<b>Total Income (1+2)</b>	<b>25,331</b>	<b>25,696</b>	<b>21,784</b>	<b>97,389</b>
<b>4</b>	<b>Expenses</b>				
	(a) Cost of materials consumed	6,265	6,791	4,838	24,009
	(b) Purchases of stock-in-trade	1,879	1,094	1,710	6,677
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	417	220	581	1,332
	(d) Employee Benefits expense	6,062	5,779	5,610	23,126
	(e) Research & Development Expense	1,112	1,312	1,321	5,152
	(f) Other Expenses	7,257	7,151	6,536	28,807
	(g) Finance Costs	612	463	718	2,054
	(h) Depreciation and Amortisation expense	1,699	1,946	1,672	7,156
	<b>Total Expenses</b>	<b>25,303</b>	<b>24,756</b>	<b>22,986</b>	<b>98,313</b>
<b>5</b>	<b>Profit/(Loss) before Tax (3-4)</b>	<b>28</b>	<b>940</b>	<b>(1,202)</b>	<b>(924)</b>
<b>6</b>	<b>Tax Expenses</b> - Current	4	-	-	-
	- Deferred	(194)	(223)	-	(719)
	- MAT Credit Adjustments	-	-	-	79
	<b>Total Tax Expenses</b>	<b>(190)</b>	<b>(223)</b>	<b>-</b>	<b>(640)</b>
<b>7</b>	<b>Profit/(Loss) for the period (5-6)</b>	<b>218</b>	<b>1,163</b>	<b>(1,202)</b>	<b>(284)</b>
<b>8</b>	<b>Other Comprehensive Income</b>				
a	i) Items that will not be reclassified to profit and loss	(15)	(72)	(3)	(81)
	ii) Income tax on relating to this item	5	25	1	28
b	i) Items that may be reclassified to profit or loss				
	<b>Total Other Comprehensive Income</b>	<b>(10)</b>	<b>(47)</b>	<b>(2)</b>	<b>(53)</b>
<b>9</b>	<b>Total Comprehensive income for the year (7+8)</b>	<b>208</b>	<b>1,116</b>	<b>(1,204)</b>	<b>(337)</b>
	<b>Profit attributable to:</b>				
	Equity Shareholders of the Company	218	1,163	(1,202)	(284)
	Non-Controlling Interest				
		<b>218</b>	<b>1,163</b>	<b>(1,202)</b>	<b>(284)</b>
	<b>Other comprehensive income is attributable to:</b>				
	Equity Shareholders of the Company	(10)	(47)	(2)	(53)
	Non-Controlling Interest				
		<b>(10)</b>	<b>(47)</b>	<b>(2)</b>	<b>(53)</b>
	<b>Total comprehensive income is attributable to:</b>				
	Equity Shareholders of the Company	208	1,116	(1,204)	(337)
	Non-Controlling Interest				
		<b>208</b>	<b>1,116</b>	<b>(1,204)</b>	<b>(337)</b>
<b>10</b>	Paid up Equity Share Capital (Face value ₹ 2/- each)	1843	1843	1843	1843
<b>11</b>	Other Equity				64,265
<b>12</b>	Earnings per share (of ₹ 2/- each)				
	(a) Basic- in ₹	0.24	1.26	(1.30)	(0.31)
	(b) Diluted- in ₹	0.24	1.26	(1.30)	(0.31)

**Notes :**

- The unaudited standalone financial results for the quarter ended 30th June, 2019 have been reviewed by the Audit committee and approved by the Board of Director of the Company at its meeting held on 13th Aug, 2019. The Statutory auditors have expressed an unmodified audit opinion on these standalone and consolidated financial results.
- The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable.
- The company has only one primary reportable segment of activity, namely, Pharmaceuticals.  
Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows:

(₹ In Lakhs)

Net Sales and Income from Operations	Quarter ended 30.06.2019 (Unaudited)	Quarter ended 31.03.2019 (Audited)	Quarter ended 30.06.2018 (Unaudited)	Year ended 31.03.2019 (Audited)
India	17,246	15,801	16,359	65,555
Outside India	7,472	8,696	4,890	28,582
<b>Total</b>	<b>24,718</b>	<b>24,497</b>	<b>21,249</b>	<b>94,137</b>

- The statutory auditors of the company have carried out limited review of the financial results for the quarter ended 30th June, 2019.
- The figures of the quarter ended 31 March 2019 are balancing figures between audited figures in respect of full financial year 31 March 2019 and the unaudited published year to date figures upto 31 December 2018 which were subjected to limited review.
- The Company has adopted IND AS 116, "Leases", effective 1 April 2019, using modified retrospective approach and there is no significant impact on the financial results.
- There are no exceptional items.

**By Order of the Board  
For Indoco Remedies Ltd.**

Place : Mumbai  
Date : 13th Aug, 2019

sd/-  
Suresh G. Kare